title: Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment.
abstract: BACKGROUND
  We sought to observe the effectiveness of intravitreal injection of ranibizumab in treating neovascular age-related macular degeneration (nAMD) with serous pigment epithelial detachment (sPED).
  
  
  METHODS
  A retrospective, noncomparative case series was performed. Twenty-3 eyes of 23 patients with sPED secondary to nAMD who had received intravitreal injections of ranibizumab were included in this study. All patients underwent best-corrected visual acuity (BCVA), synchronous fluorescein fundus angiography (FFA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT) examinations. All patients were treated with pro re nata intravitreal injections after 3 loading doses of ranibizumab and were followed up for 12 months. The differences in the BCVAs, maximum PED heights, PED volumes and CFTs of the affected eyes were compared between the baseline and last visit.
  
  
  RESULTS
  Twelve months after the first injection, improved visual acuity was observed in 16 of the 23 eyes. 4 eyes exhibited stable visual acuity, and 3 eyes exhibited impaired visual acuity. The mean post-injection logMAR BCVA was 0.58±0.05, which was much better than that at baseline (0.76±0.08; t=1.751, P=0.0869). The mean maximum PED height at baseline was 350.17±35.73 μm and it was decreased to 238.87±36.87 μm (t=2.192, P=0.0337) at the last visit. The mean PED volume after injection was 0.34±0.1 mm(3), which was significantly decreased compared with that at baseline (0.81±0.21 mm(3); t=2.021, P=0.0494).The mean CFT decreased, but this difference was not statistically significant (t=1.003, P=0.3211). None of the patients exhibited endophthalmitis, uveitis or RPE tears.
  
  
  CONCLUSIONS
  Intravitreal injection of ranibizumab for the treatment of neovascular age-related macular degeneration with serous pigment epithelial detachment safely and effectively improved the patients' visual acuities and decreased their PED heights volumes.
authors.affiliation: Department of Ophthalmology, Affiliated Shanghai Tenth Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
authors.forename: Chun
authors.initials: C
authors.lastname: Zhao
authors.affiliation: Department of Ophthalmology, Affiliated Shanghai Tenth Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Ophthalmology, Tenth People's Hospital of Tongji University, Shanghai, China (mainland).
authors.forename: Lei
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Ophthalmology, Affiliated Shanghai Tenth Clinical Medical College of Nanjing Medical University, Shanghai, China (mainland).
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.affiliation: Department of Ophthalmology, Tenth People's Hospital of Tongji University, Shanghai, China (mainland).
authors.forename: Ding
authors.initials: D
authors.lastname: Xu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000008:administration & dosage* / Q000627:therapeutic use*; D012163:Retinal Detachment / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D055213:Retinal Pigment Epithelium / Q000187:drug effects / Q000473:pathology*; D057135:Wet Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000069579:Ranibizumab